Leptospirosis Market Size (2024 - 2029)

Leptospirosis Market Analysis

The leptospirosis market is projected to register a CAGR of 6.1% during the forecast period.

The COVID-19 pandemic severely impacted the leptospirosis market initially, with the temporary cancellation or delays in diagnosing and treating various non-COVID diseases, including leptospirosis infection. However, several countries reported growth in leptospirosis cases amid the outbreak. For instance, a study published in the Journal of Medical Virology in September 2022 stated that leptospirosis and coronavirus infection was endemic in the coastal regions of South India during the pandemic. Although, in the post-pandemic period, the cases of COVID-19 decreased, which led to the resumption of the leptospirosis treatment, which enabled the market to grow at the normal growth pace.

The leptospirosis market is expected to grow during the forecast period owing to the increase in the prevalence of leptospirosis and a surge in research and development activities for bacterial infections. For instance, a study published in Journal Pathogen in March 2022 stated that human leptospirosis infection is a leading and neglected source of morbidity and mortality, with more than 1 million cases and approximately 60,000 deaths per year. Further, a study published in the Journal Scientific Reports in January 2022 stated that a sampling of United States Virgin Islands (USVI) rodents determined that 45.7% (64/140) were carriers of pathogenic Leptospira species. The study stated that rodent exposure is associated with an increased risk of leptospirosis. The study also revealed that acute infections are more common in low-resource, tropical, and subtropical locations where outbreaks occur after natural disasters such as hurricanes, heavy rainfall, and flooding. With such a vast target population for leptospirosis infections, the market is likely to grow with higher demand for leptospirosis infection treatment in the coming years.

Furthermore, the activities in the research and developments for bacterial infections have increased, which is expected to boost the R&D of more leptospirosis treatment drugs and boost the market growth. For instance, in December 2021, a Research Project Grant from the Health Research Council of New Zealand (HRC) was awarded funding of NZD 1 million (USD 0.61 million) to Professor Jackie Benschop from the School of Veterinary Science. The research grant was awarded for the project "Enhancing leptospirosis diagnosis and outcomes for rural and Māori communities."

Therefore, the studied market is anticipated to grow over the analysis period due to the factors above, including the increasing prevalence of leptospirosis and the surge in research and development activities for bacterial infections. However, the lack of awareness about leptospirosis infections will likely impede market growth.

Leptospirosis Industry Segmentation

As per the scope of the report, leptospirosis is a zoonotic illness that can spread from animals to humans, and it can infect both people and animals. Leptospirosis can be acquired through the nose, mouth, eyes, or skin abrasions when a person encounters water that the infected animals have polluted. The Leptospirosis Market is Segmented by Treatment Type (Penicillin, Ampicillin, Doxycycline, Ceftriaxone, Azithromycin, Tetracycline, and Others), Diagnosis (Microscopic Agglutination Test, Complete Blood Count, Urinalysis, and Others), and End Users (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for five different major regions globally.